Chromosome 13q deletion and IgH abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: a combined morphology and I-FISH analysis
- PMID: 17590504
- DOI: 10.1016/j.canlet.2007.05.005
Chromosome 13q deletion and IgH abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: a combined morphology and I-FISH analysis
Abstract
Ploidy status and chromosomal aberrations involving chromosome 13q and the immunoglobulin heavy chain locus (IgH) are important prognostic features in multiple myeloma (MM). However, conventional cytogenetic studies are often not reveling and determination of plasma cells (PC) ploidy status in MM is technically difficult. We have used a combined cell morphology and interphase FISH (I-FISH) analysis in 184 consecutive BM samples from 136 MM patients for the diagnosis of chromosome 13q deletion [del (13q)] and IgH abnormalities. We have found a high prevalence (37%) of near-tetraploid (NT) PC in the BM samples studied. NT status of PC was verified with DNA index (DI) measurements. del (13q) was found in 69% and a total absence of one IgH copy (loss of IgH) in 20% of NT samples. We have shown that the presence of del (13q) and loss of IgH can be masked in NT cases: in 12 NT samples originally identified as normal for del (13q) the abnormality was obscured in the majority of plasma cells due to the presence of NT. Similarly, loss of IgH was masked in four samples with a large population of NT cells. Moreover, in one case the appearance of a 100% tetraploidy during disease progression masked the presence of del (13q), originally present, and could therefore falsely appear as disappearance of this prognostic marker. In conclusion, we have shown that a combination of three abnormalities, i.e., del (13q), loss of IgH and NT, all of potential prognostic significance, can be overlooked unless NT is specifically searched for and ruled out. Therefore, we suggest that a search for NT should be added to the routine BM assessment in MM patients.
Similar articles
-
Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.Exp Oncol. 2007 Jun;29(2):116-20. Exp Oncol. 2007. PMID: 17704743
-
Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark.Cancer Genet Cytogenet. 2007 Apr 15;174(2):89-99. doi: 10.1016/j.cancergencyto.2006.11.015. Cancer Genet Cytogenet. 2007. PMID: 17452249
-
Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridization.Cancer Genet Cytogenet. 2005 Apr 15;158(2):99-109. doi: 10.1016/j.cancergencyto.2005.01.006. Cancer Genet Cytogenet. 2005. PMID: 15796956
-
The prognostic significance of cytogenetics and molecular profiling in multiple myeloma.Cancer Genet. 2011 Jan;204(1):3-12. doi: 10.1016/j.cancergencyto.2010.11.002. Cancer Genet. 2011. PMID: 21356186 Review.
-
Cutaneous involvement in multiple myeloma: a clinicopathologic, immunohistochemical, and cytogenetic study of 8 cases.Arch Dermatol. 2003 Apr;139(4):475-86. doi: 10.1001/archderm.139.4.475. Arch Dermatol. 2003. PMID: 12707095 Review.
Cited by
-
Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma.Am J Hematol. 2019 May;94(5):E117-E120. doi: 10.1002/ajh.25420. Epub 2019 Feb 6. Am J Hematol. 2019. PMID: 30680770 Free PMC article. No abstract available.
-
Establishment of cell lines from both myeloma bone marrow and plasmacytoma: SNU_MM1393_BM and SNU_MM1393_SC from a single patient.Biomed Res Int. 2014;2014:510408. doi: 10.1155/2014/510408. Epub 2014 Aug 12. Biomed Res Int. 2014. PMID: 25343143 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials